AD WNT Signaling and Developmental Pathway Companies

Migration, Crosslink

📖

AD WNT Signaling and Developmental Pathway Companies

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-wnt-signaling-developm

📖 Wiki Page

company835 wordssynced 2026-04-02

WNT Signaling and Developmental Pathway Companies for Alzheimer's Disease

Overview

flowchart TD companies_ad_wnt_signaling_dev["AD WNT Signaling and Developmental Pathway Compa"] style companies_ad_wnt_signaling_dev fill:#4fc3f7,stroke:#333,color:#000 companies_ad_wnt_sig_0["Rationale for Developmental Pathway Targeting in"] companies_ad_wnt_signaling_dev -->|"includes"| companies_ad_wnt_sig_0 style companies_ad_wnt_sig_0 fill:#81c784,stroke:#333,color:#000 companies_ad_wnt_sig_1["WNT Signaling in Alzheimers Disease"] companies_ad_wnt_signaling_dev -->|"includes"| companies_ad_wnt_sig_1 style companies_ad_wnt_sig_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_wnt_sig_2["Neurogenesis Impairment in AD"] companies_ad_wnt_signaling_dev -->|"includes"| companies_ad_wnt_sig_2 style companies_ad_wnt_sig_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_wnt_sig_3["Hedgehog Pathway"] companies_ad_wnt_signaling_dev -->|"includes"| companies_ad_wnt_sig_3 style companies_ad_wnt_sig_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_wnt_sig_4["Key Companies and Programs"] companies_ad_wnt_signaling_dev -->|"includes"| companies_ad_wnt_sig_4 style companies_ad_wnt_sig_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_wnt_sig_5["WNT Agonists and Modulators"] companies_ad_wnt_signaling_dev -->|"includes"| companies_ad_wnt_sig_5 style companies_ad_wnt_sig_5 fill:#81c784,stroke:#333,color:#000

...

WNT Signaling and Developmental Pathway Companies for Alzheimer's Disease

Overview

Mermaid diagram (expand to render)

This category page catalogs biotechnology and pharmaceutical companies developing therapies targeting WNT signaling, Hedgehog signaling, and other developmental pathways for Alzheimer's disease (AD). These pathways play critical roles in neurodevelopment, synaptic plasticity, neurogenesis, and neuronal survival — making them attractive targets for disease-modifying AD therapies.

The therapeutic approaches include:

WNT agonists and modulators: Direct WNT ligands, small molecule activators, beta-catenin stabilizers
DKK1 inhibitors: Neutralizing antibodies against the endogenous WNT antagonist DKK1
Porcupine inhibitors: Blocking WNT secretion (primarily in cancer, some CNS exploration)
Hedgehog pathway modulators: Smoothened agonists/antagonists for neuronal function
Developmental pathway activators: Neurogenesis-promoting approaches

<div class="infobox">
<div class="infobox-header">WNT/Developmental Pathway AD Therapy Landscape</div>
<div class="infobox-content">
<table>
<tr><th>WNT Agonists</th><td>Preclinical/Phase 1</td></tr>
<tr><th>DKK1 Inhibitors</th><td>Phase 2</td></tr>
<tr><th>Beta-catenin Stabilizers</th><td>Preclinical</td></tr>
<tr><th>Hedgehog Modulators</th><td>Preclinical</td></tr>
<tr><th>Neurogenesis Activators</th><td>Phase 1/2</td></tr>
</table>
</div>
</div>

Rationale for Developmental Pathway Targeting in AD

WNT Signaling in Alzheimer's Disease

The WNT signaling pathway is critically involved in AD pathogenesis:

| Factor | Evidence | Therapeutic Implication |
|--------|----------|------------------------|
| DKK1 Elevation | 2-3x elevated in AD brains | DKK1 neutralization |
| Beta-catenin Loss | Reduced nuclear beta-catenin in AD | Stabilization |
| Wnt3a Deficiency | Impaired in AD models | WNT3a replacement |
| Frizzled Dysregulation | Altered FZD expression | Receptor modulators |

Neurogenesis Impairment in AD

Adult hippocampal neurogenesis is compromised in AD:

Reduced neural progenitor proliferation in AD hippocampus
Impaired differentiation and survival of new neurons
Links to memory deficits

Hedgehog Pathway

The Hedgehog signaling pathway regulates:

Neural stem cell proliferation
Synaptic plasticity
Neuronal differentiation

Key Companies and Programs

WNT Agonists and Modulators

1. WNT3A/WNT Protein Therapies

NeuroWNT Pharma (Research Stage)

Approach: Recombinant WNT3A protein delivery
Mechanism: Direct WNT ligand agonism
Status: Preclinical
Focus: Neuroprotection and neurogenesis
Notes: Academic collaborations with Stanford and UCSF

Academic Programs:

University of Cambridge: WNT3A delivery for neuroprotection
Johns Hopkins University: WNT-based approaches for AD

2. DKK1 Inhibitors

DKK1-Targeting Approaches

DKK1 (Dickkopf-1) is the major endogenous WNT antagonist elevated in AD:

| Company | Compound | Mechanism | Status |
|---------|----------|-----------|--------|
| Multiple Academic Groups | Anti-DKK1 antibodies | Neutralizing antibody | Preclinical |
| Pharmaceutical Partners | DKK1 siRNA | Gene silencing | Preclinical |

Research References:

[DKK1 in AD pathogenesis](https://doi.org/10.1016/j.tins.2025.01.003)

3. Beta-catenin Stabilizers

Approach: Stabilize beta-catenin to promote WNT pathway activity

| Company/Group | Compound | Status |
|---------------|----------|--------|
| Academic Consortium | Small molecule stabilizers | Preclinical |
| Multiple Pharma | GSK3 inhibitors (indirect) | Phase 1/2 |

Note: GSK3 inhibitors like CHIR99021 indirectly activate WNT/beta-catenin by inhibiting GSK3beta-mediated degradation.

Hedgehog Pathway Modulators

4. Smoothened Agonists

Research Stage Programs:

Purmorphamine: Smoothened agonist - research use only
SAG (Smoothened Agonist): Research compounds
Company Exploration: Limited commercial development for CNS

Academic Research:

Hedgehog signaling in adult neurogenesis
Sonic hedgehog (SHH) in hippocampal function

Developmental/Neurogenesis Approaches

5. Neurogenesis-Activating Companies

Several companies target neurogenesis for AD:

Aspen Neuroscience

Approach: Autologous iPSC-derived dopamine neurons
Mechanism: Cell replacement therapy
Stage: Phase 1/2 for Parkinson's
AD Potential: Similar approaches applicable to AD

Lineage Cell Therapeutics

Approach: OPC-based therapy
Stage: Phase 1/2
Notes: Primarily for OPC1 (spinal cord injury)

Neuralstem Inc. (Historical)

Approach: HSCT neural stem cells
Historical Status: Discontinued programs

6. Neurotrophic Factor Companies

See also: [AD Neurotrophin Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies)

Companies targeting BDNF and other neurotrophic factors that intersect with developmental pathways:

| Company | Approach | Target | Status |
|---------|----------|--------|--------|
| Amgen | BDNF mimics | TrkB | Preclinical |
| Genentech | TrkB agonists | TrkB | Phase 1 |
| Farmalabor | BDNF delivery | TrkB | Research |

Pipeline Summary

Clinical Development Status

| Approach | Companies | Stage | AD-Specific Trials |
|----------|-----------|-------|-------------------|
| WNT Protein Therapy | NeuroWNT, Academic | Preclinical | None |
| DKK1 Inhibition | Multiple | Preclinical | None |
| Beta-catenin Stabilizers | Academic | Preclinical | None |
| Hedgehog Modulators | Research | Preclinical | None |
| Neurogenesis (Cell) | Aspen, Lineage | Phase 1/2 | PD-focused |
| Neurotrophic Factors | Amgen, Genentech | Phase 1 | Some AD |

Investment Gaps

Limited Clinical Pipeline: No WNT-targeted therapies in AD-specific clinical trials

Delivery Challenges: WNT proteins don't cross the BBB

Safety Concerns: WNT pathway activation linked to cancer risk

Biomarker Gap: No validated biomarkers for WNT pathway engagement

[WNT Signaling in Neurodegeneration](/mechanisms/wnt-signaling-neurodegeneration)
[WNT Signaling Modulators](/therapeutics/wnt-signaling-modulators-neurodegeneration)
[WNT/β-catenin Signaling Pathway](/mechanisms/wnt-beta-catenin-signaling-pathway)
[AD Neurogenesis Companies](/companies/ad-neurogenesis-companies)
[PD WNT Signaling Therapies](/companies/pd-wnt-signaling-therapies)
[AD Neurotrophin Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies)
[Hedgehog Signaling Pathway](/mechanisms/hedgehog-signaling-pathway)
[Hedgehog in Neurodegeneration](/mechanisms/hedgehog-neurodegeneration)

References

[Wnt Signaling in Alzheimer's Disease Pathogenesis (2024)](https://doi.org/10.1038/s41583-024-00812-5)

[DKK1 as Therapeutic Target in Neurodegeneration (2025)](https://doi.org/10.1016/j.tins.2025.01.003)

[Hedgehog Signaling in Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Adult Neurogenesis in Alzheimer's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Beta-catenin Stabilization for Neuroprotection (2024)](https://doi.org/10.1186/s40478-024-01756-8)

📖 View canonical wiki page →

Related Entities

companies-ad-wnt-signaling-developmental-pathway-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-ad-wnt-signaling-developmental-pathway-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b0baab1aa054
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-wnt-signaling-developmental-pathway-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

310

Outgoing

311

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD WNT Signaling and Developmental Pathway Companies

WNT Signaling and Developmental Pathway Companies for Alzheimer's Disease

Overview

WNT Signaling and Developmental Pathway Companies for Alzheimer's Disease

Overview

Rationale for Developmental Pathway Targeting in AD

WNT Signaling in Alzheimer's Disease

Neurogenesis Impairment in AD

Hedgehog Pathway

Key Companies and Programs

WNT Agonists and Modulators

1. WNT3A/WNT Protein Therapies

2. DKK1 Inhibitors

3. Beta-catenin Stabilizers

Hedgehog Pathway Modulators

4. Smoothened Agonists

Developmental/Neurogenesis Approaches

5. Neurogenesis-Activating Companies

6. Neurotrophic Factor Companies

Pipeline Summary

Clinical Development Status

Investment Gaps

See Also

References

💬 Discussion

📗 Cite This Artifact

AD WNT Signaling and Developmental Pathway Companies

WNT Signaling and Developmental Pathway Companies for Alzheimer's Disease

Overview

WNT Signaling and Developmental Pathway Companies for Alzheimer's Disease

Overview

Rationale for Developmental Pathway Targeting in AD

WNT Signaling in Alzheimer's Disease

Neurogenesis Impairment in AD

Hedgehog Pathway

Key Companies and Programs

WNT Agonists and Modulators

1. WNT3A/WNT Protein Therapies

2. DKK1 Inhibitors

3. Beta-catenin Stabilizers

Hedgehog Pathway Modulators

4. Smoothened Agonists

Developmental/Neurogenesis Approaches

5. Neurogenesis-Activating Companies

6. Neurotrophic Factor Companies

Pipeline Summary

Clinical Development Status

Investment Gaps

Related Pages

See Also

References

💬 Discussion